Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients

British Journal of Cancer

Volumn 118, Issue 10, 2018, Pages 1296-1301

  Bins, Sander ^a   Basak, Edwin A ^a   El Bouazzaoui, Samira ^b   Koolen, Stijn L W ^a   Oomen De Hoop, E ^a   Van Der Leest, Cor H ^c   Van Der Veldt, Astrid A M ^a   Sleijfer, Stefan ^a   Debets, Reno ^a   Van Schaik, Ron H N ^b   Aerts, Joachim G J V ^b   Mathijssen, Ron H J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BILIRUBIN; GAMMA INTERFERON; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN KINASE ZAP 70; PROTEIN TYROSINE PHOSPHATASE SHP 2; STEROID; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR PROTEIN;

ADULT; ADVERSE DRUG REACTION; ALLELE; ARTICLE; CARCINOGENESIS; CLINICAL PRACTICE; COHORT ANALYSIS; COLITIS; DIARRHEA; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PNEUMONIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; TOXICITY; TREATMENT DURATION; AGED; DRUG EFFECT; GENETIC ASSOCIATION STUDY; GENETICS; MIDDLE AGED; PATHOLOGY; T LYMPHOCYTE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NIVOLUMAB; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 85046020618     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/s41416-018-0074-1     Document Type: Article

References (27)

1. Debets, R., Donnadieu, E., Chouaib, S. &Coukos, G. TCR-engineered T cells to treat tumours: Seeing but not touching? Semin. Immunol. 28, 10-21 (2016).
2. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
3. Nishimura, H., Nose, M., Hiai, H., Minato, N. &Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motifcarrying immunoreceptor. Immunity 11, 141-151 (1999).
4. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumours: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
5. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
6. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
7. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med 373, 1803-1813 (2015).
8. Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repairdeficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182-1191 (2017).
9. Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856-1867 (2016).
10. Hertz, D. L. &Rae, J. Pharmacogenetics of cancer drugs. Annu Rev. Med. 66, 65-81 (2015).
11. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. &Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signalling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 98, 13866-13871 (2001).
12. Sheppard, K. A. et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signalling to PKCtheta. FEBS Lett. 574, 37-41 (2004).
13. Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra137 (2012).
14. Lee, Y. H., Bae, S. C., Kim, J. H. &Song, G. G. Meta-analysis of genetic polymorphisms in programmed cell death 1 Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z. Rheumatol. 74, 230-239 (2015).
15. Chen, S. et al. The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review. Rheumatol. Int. 36, 33-44 (2016).
16. Bouzid, D. et al. Association of ZAP70 and PTPN6, but Not BANK1 or CLEC2D, with inflammatory bowel disease in the Tunisian population. Genet Test. Mol. Biomark. 17, 321-326 (2013).
17. Kim, K. et al. Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus. Ann. Rheum. Dis. 69, 1247-1250 (2010).
18. Narumi, Y. et al. Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population. J. Clin. Immunol. 29, 303-310 (2009).
19. Hamajima, N., Naito, M., Kondo, T. &Goto, Y. Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci. 97, 1129-1138 (2006).
20. Johnson, A. D. et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 24, 2938-2939 (2008).
21. Lewis, C. M. Genetic association studies: design, analysis and interpretation. Brief. Bioinform. 3, 146-153 (2002).
22. Peduzzi, P., Concato, J., Kemper, E., Holford, T. R. &Feinstein, A. R. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 49, 1373-1379 (1996).
23. Spain, L., Diem, S. &Larkin, J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 44, 51-60 (2016).
24. Postow, M. A. Managing immune checkpoint-blocking antibody side effects. Am. Soc. Clin. Oncol. Educ. Book 35, 76-83 (2015).
25. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmall-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
26. Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
27. Sivan, A. et al. Commensal Bifidobacterium promotes antitumour immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084-1089 (2015).